TX-FLUENCE
7.4.2022 15:02:07 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, released results from its intercanopy lighting research in collaboration with Wageningen University & Research (WUR). Fluence’s research showed that intercanopy lighting treatments at a high intensity combined with top light increased yield in Hi Power and Skyson cucumber cultivars as well as Merlice and Brioso tomato cultivars.
Following Fluence’s multiyear research on the overall effects of broad-spectrum lighting solutions on plant development, Fluence and WUR further investigated the effects of various light distributions and intensities on plant morphology and fruit quality throughout a winter season.
“Growers have used the same benchmarks for vine crop lighting strategies for decades. Those benchmarks were typically derived from crops grown under high-pressure sodium fixtures that limited potential light intensity due to excess heat,” said David Hawley, principal scientist for Fluence. “LEDs virtually eliminate that restriction. As Fluence seeks to explore how to empower growers to be as productive as possible by maximizing their bottom lines, we wanted to investigate not only how higher intensities affect crops, but how crops use energy within the canopy. Our research overwhelmingly showed that intercanopy lighting in tandem with a top light strategy at a higher intensity boosted yields over conventional lighting strategies.”
Fluence and WUR studied cucumbers and tomatoes in the Netherlands under four light treatments: top light only at 250 µmol/m-2 /s-1 , top light and intercanopy lighting at 250 µmol/m-2 /s-1 , top light only at 375 µmol/m-2 /s-1 , and top light and intercanopy lighting at 375 µmol/m-2 /s-1 . Under the treatments with both top light and intercanopy lighting, two-thirds of the total PPFD were applied to the top of the canopy with Fluence’s VYPR luminaire, with the other third applied through Fluence’s VYNE intercanopy light.
Key findings from the studies include:
- Adding intercanopy lighting at the higher total intensity increased cumulative yield in both cucumber cultivars up to 110% compared to the top light-only treatment at the lower intensity.
- Similarly, adding intercanopy lighting at the higher total intensity enabled a less aggressive pruning strategy that, in combination with the higher light intensity, also increased the cumulative number of cucumber fruits in both cultivars up to 53% compared to the top light-only treatment at the lower intensity.
- Both cucumber cultivars also saw a decrease in total plant height and more compact morphology at the higher intensity treatments.
- Adding intercanopy lighting at the higher total intensity also increased cumulative yield and the total number of fruits up to 62% and 57%, respectively, in both tomato cultivars over the top light-only treatment at the lower intensity.
To ensure high-quality crops year-round, cucumber and tomato greenhouse growers often explore supplemental lighting strategies to adequately light plants during darker fall and winter months. With Fluence and WUR’s latest intercanopy lighting research, growers can now consider additional light distribution options to optimize yield and quality to meet their cultivation goals.
For more information on Fluence and its ongoing research initiatives, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom